IDEXX Laboratories Inc (IDXX)vsMedpace Holdings Inc (MEDP)
IDXX
IDEXX Laboratories Inc
$504.70
-0.36%
HEALTHCARE · Cap: $40.98B
MEDP
Medpace Holdings Inc
$587.52
+0.75%
HEALTHCARE · Cap: $16.49B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 64% more annual revenue ($4.55B vs $2.78B). IDXX leads profitability with a 25.0% profit margin vs 17.7%. MEDP appears more attractively valued with a PEG of 2.81. MEDP earns a higher WallStSmart Score of 68/100 (B-).
IDXX
Buy63
out of 100
Grade: C+
MEDP
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.7%
Fair Value
$436.26
Current Price
$504.70
$68.44 premium
Margin of Safety
-39.2%
Fair Value
$304.57
Current Price
$587.52
$282.95 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Every $100 of equity generates 113 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.8%
17.2% revenue growth
Earnings expanding 37.1% YoY
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 24.7x book value
Premium valuation, high expectations priced in
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 37.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 20.8%. Revenue growth of 17.2% demonstrates continued momentum.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
IDXX profiles as a mature stock while MEDP is a growth play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
MEDP is growing revenue faster at 17.2% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (68/100 vs 63/100), backed by strong 17.7% margins and 17.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?